Do You Qualify for Wegovy in Canada?
By GLP1Prescription Editorial
Last verified
Pending clinical review
The two-minute check
Five questions about where you live and where you are in the process. It asks nothing about your health, sends nothing anywhere, and stores nothing beyond your own browser tab.
Question 1 of 4
Which province or territory do you live in?
Online providers are licensed province by province, so this is the one answer that decides whether there is a route at all.
Nothing you selected was sent to a server or written to a database. There is no table for it — your answers live in this browser tab and disappear when you close it.
The phrase people search is "Wegovy eligibility BMI", and here is its honest shape: providers publish BMI-based intake criteria for their programs, and a licensed clinician — not you, and not any website — applies them to your application. The check above settles the part that is yours to settle: whether an online visit can start from your province.
All commercial facts on this page were last verified on 2026-08-14, except Quebec’s 2026 public-plan coverage decision, which carries its own earlier date below. The full paperwork picture — prescriber rules, the Quebec coverage story, renewals — lives on the Wegovy requirements page; this page stays on eligibility itself.
Where BMI actually enters the process
Provider intake forms collect height and weight, calculate body-mass index from them, and put the result in front of a reviewing clinician. That number is screened against the provider’s published intake criteria — applied by the clinician, and quoted nowhere on this page. Felix does publish intake criteria for its weight-management line on its own site (verified 2026-08-14). We do not reproduce the thresholds here, and that is a deliberate choice rather than a gap: a screening number lifted onto a third-party page reads as a rule, gets stale the moment the provider revises it, and belongs to the clinician applying it rather than to the reader measuring themselves against it.
Self-screening against a number found online is not how the decision works in either direction: an application matching every published criterion can still be declined, because the clinician’s judgment is the deciding layer. The check above never asks height or weight — it routes on province and situation only, and there is no table in this site’s database for a health answer to land in.
Wegovy-specific access notes
- Wegovy is a Novo Nordisk semaglutide product, and a separate product from Ozempic. Its formats, strengths, and regulatory status are not something we have verified, so this page states none of them; official product listings carry them.
- Felix publishes a per-pen price for brand-name Wegovy. $374.82 per pen at every dose it lists — 0.25mg, 0.5mg, 1mg and above (verified 2026-08-14). Felix states these prices are for patients in Ontario, do not account for insurance coverage, and reflect the cost after its Patient Support Program discount is applied.
- No provider here sells Wegovy at a flat monthly rate, because none of them sells medication that way. Felix bills per pen, and its visit fees are separate again: $0 for the initial visit, then $40 per follow-up visit. Hims Canada lists Wegovy among the medications it offers but publishes no price for it, stating the estimated cost per refill is shown during the online visit, alongside a $12.99 pharmacy fill fee on each refill. Maple’s medication is billed by the dispensing pharmacy rather than by Maple. All verified 2026-08-14.
- Quebec’s public plan declined Wegovy coverage in April 2026, after pan-Canadian Pharmaceutical Alliance negotiations ended without an agreement (verified 2026-08-12, and not re-checked in our 2026-08-14 review — it is the oldest fact on this page). That is a coverage fact rather than an access fact — Quebec’s separate access gate is below.
Provinces where the check ends early
The check above ends with an exit ramp instead of a provider list when your province has no partnered online option. Quebec is the clearest case: Felix serves no line there at all (verified 2026-08-14), and our Quebec page documents what actually exists instead — Maple’s per-visit telehealth at its own Quebec pricing, the public system’s routes, and Quebec pharmacists’ authority over existing prescriptions, each cited to the body that published it.
New Brunswick, Nova Scotia, and Newfoundland and Labrador sit outside Felix’s line as well. In those three provinces there are two published routes to ask about: Hims Canada says it is available in all ten provinces, and Maple states its practitioners are available in every province and territory (both verified 2026-08-14). One carve-out belongs to Nova Scotia specifically — Maple lists its named Weight Medication Assessment specialty everywhere except Nova Scotia, Nunavut, and the Northwest Territories (verified 2026-08-14) — so a Nova Scotia reader has Maple’s general practitioner access but not that named specialty.
The three territories are a separate question with a separate answer, and each provider answers it differently. Felix serves no territory. Hims Canada names no territory anywhere on its published pages, which is silence rather than a yes or a no, and we do not read it either way. Maple’s territory statement covers all three, but the specialty exclusion above removes Nunavut and the Northwest Territories — which leaves Yukon as the one territory with a documented route for that specialty (all verified 2026-08-14).
Inside the six provinces Felix’s line does serve, the next question is what the assessment costs — and at Felix the initial visit is $0, with $40 due on each follow-up visit (verified 2026-08-14).
Wegovy eligibility FAQs
Do I need to know my BMI before using the check above?
Where do the actual BMI criteria live, if not on this page?
Which provider publishes a price for brand-name Wegovy?
Does Quebec’s 2026 coverage decision change whether I can apply online?
From here: the Wegovy requirements page for the checklist and prescriber table, consultation fees for the assessment step, and the providers hub for who would review your file.
Health Canada compliance: GLP1Prescription.ca documents provider fees, provinces served, and the prescription process only. We do not make therapeutic claims. This website does not provide medical advice. Consult your healthcare provider about medication options.
Update log
- First published. All provider fees and coverage verified 2026-08-12.
- Corrected against a first-party re-check. The page’s central hedge — that no provider on our list publishes a rate for brand-name Wegovy — is withdrawn: Felix publishes $374.82 per pen at every dose it lists. Felix’s "$149 per month all-in" and Hims Canada’s "$149 per month for brand Ozempic" are both withdrawn as unpublished; Felix bills per pen with separate visit fees, and Hims publishes no medication price by policy. Felix visit fees restated with the $40 follow-up charge the page had omitted; that pass also read the initial visit off Felix’s pricing page as a $99 list price shown as free, superseded the same day by the entry below. Felix’s published intake criteria are now acknowledged as existing, with the thresholds still deliberately unprinted. Province and territory copy split apart so no claim about Hims Canada carries over to the territories. Quebec’s 2026 public-plan coverage decision was not re-checked and keeps its 2026-08-12 date.
- Felix’s consultation fee settled at a plain $0. The correction above had inferred a two-clause price — a $99 list price currently shown as free — from a struck-through $99 on Felix’s pricing block and a "$99 initial program fee" sentence in its pricing blog post. The site owner, who holds the direct relationship with Felix, confirmed the same day that the consultation fee is $0 and is staying $0; first-hand knowledge of what a reader pays outranks an inference read off a page, so both fee passages on this page state $0 (verified 2026-08-14). The two page observations are kept in our verification record, relabelled as superseded for publication, so the next re-check starts from the evidence. Unchanged: the $40 follow-up visit fee, separately sourced, and Felix’s $374.82-per-pen Wegovy price with its Ontario and Patient Support Program qualifiers.
Related
Wegovy prescription requirements
The checklist, the prescriber table, and Quebec’s 2026 public-plan coverage decision.
ViewDo you qualify for Ozempic?
The other Novo Nordisk semaglutide product, and what each provider publishes for it.
ViewWhat an online consultation costs in Canada
What each provider charges to assess you, and what that fee does and does not buy.
View